header image

Take a look through our annual reports.

How to contact us for media/press enquiries.

Have a comment or question? Get in touch.

News

Octapharma USA Grant Funds First National Camp Exchange Program for Bleeding Disorders Community Camps

07-13-2017

HOBOKEN, N.J. (July 13, 2017) – Octapharma USA has provided a grant to fund the first National Camp Exchange (NCE) for the bleeding disorders community, an adjunct program of the North American Camping Conference of Hemophilia...

Octapharma symposium at ISTH Berlin supports progress in lifelong treatment of high-risk patients with Von Willebrand disease (VWD) and haemophilia A

07-11-2017

Lachen, Switzerland, July 11th 2017: Octapharma is pleased to announce the success of yesterday’s symposium at the International Society on Thrombosis and Haemostasis (ISTH) congress held in Berlin, Germany. As platinum sponsors...

ISTH 2017, Berlin: Octapharma presents exciting Nuwiq® data in previously untreated patients and demonstrates real-life value of personalised prophylaxis for Haemophilia A

07-10-2017

Lachen, Switzerland, July 10th 2017: Octapharma is playing a prominent role this week at the International Society on Thrombosis and Haemostasis (ISTH) Congress in Berlin, Germany. As a platinum sponsor of the congress,...

Octapharma activities prominent at the upcoming 2017 ISTH Congress in Berlin, Germany

07-06-2017

Lachen, Switzerland, July 6th, 2017 – Octapharma today announced that it will be actively involved in a wide range of activities at this year’s International Society on Thrombosis and Haemostasis (ISTH) Congress. The Congress...

Octapharma USA Appoints Senior Biopharmaceutical Executive Richard E. Walters, Jr. as Vice President of Commercial Development

06-07-2017

HOBOKEN, N.J. (June 5, 2017) – Octapharma USA has appointed Richard E. Walters, Jr. as Vice President of Commercial Development, assuming immediate responsibility for all U.S. product marketing, commercial development and...

Octapharma underlines strong commitment to haemophilia A patients with the publication of new clinical data on PK-guided personalized prophylaxis according to the NuPreviq Approach with Nuwiq®

05-22-2017

Lachen, Switzerland, May 22nd 2017: Octapharma announces positive new clinical data in 66 previously treated patients (PTPs) with severe haemophilia A (HA) undergoing PK-guided personalized prophylaxis with Nuwiq® according to...

FDA Grants Octapharma USA Orphan Drug Designation for Octagam® 10% for the Treatment of Dermatomyositis

05-17-2017

HOBOKEN, N.J. (May 17, 2017) – The U.S. Food and Drug Administration (FDA) has granted Octapharma USA orphan drug designation for Octagam® Immune Globulin Intravenous (Human) 10% Liquid for the treatment of dermatomyositis, a...

Page 1 Page 2 next